English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Plus monthly

Global: Zendy Tools annual

Global: Zendy Tools monthly

Global: Zendy Free Plan

TO THE EDITOR—We greatly appreciated the article of Scherrer et al [1] evaluating viral response to combination antiretroviral therapy (cART) in patients with subtype B (34.3% previously exposed to suboptimal therapies, P < .001) and nonsubtype B human immunodeficiency virus type 1 (HIV-1). The study brings to mind a similar article by Geretti et al [2], but we found particularly reasonable the choice of Scherrer et al to restrict the analysis to a single ethnic group (whites), thus avoiding potential biases caused by ethnicity. The authors demonstrated that virological failure was higher in patients with subtype B; in particular, subtype A and CRF02_AG infections were associated with lower virological failure rates. Because certain non-B subtypes do not seem more susceptible to some drugs, why should these patients have a better response to cART? A lower propensity to select for nucleoside reverse-transcriptase inhibitor– and protease inhibitor–related mutations has been suggested for some non-B subtypes by Soares et al [3]. It is our hypothesis that pretherapy differences might explain the improved

Improved Virological Outcome in Non-B Patients: A Possible Role for Baseline Coreceptor Tropism